Article
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.
Oncotarget - 27 Sept 2016
Brighenti Elisa, Giannone Ferdinando Antonino, Fornari Francesca, Onofrillo Carmine, Govoni Marzia, Montanaro Lorenzo, Treré Davide, Derenzini Massimo
Abstract excerpt
Chronic inflammation is a risk factor for the onset of cancer and the regular use of aspirin reduces the risk of cancer development. Here we showed that therapeutic dosages of aspirin counteract the pro-tumorigenic effects of the inflammatory cytokine interleukin(IL)-6 in cancer and non-cancer cell lines, and in mouse liver in vivo. We found that therapeutic dosages of aspirin prevented IL-6 from inducing the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.